Advances in the understanding of pathogenesis, diagnosis, and therapy of light chain amyloidosis

D Bhutani, S Bal, S Rubinstein - Frontiers in Oncology, 2023 - frontiersin.org
Amyloid light chain (AL) amyloidosis is a clonal plasma cell disorder leading to production of
misfolded monoclonal immunoglobulin light chains which result in organ damage, most …

[HTML][HTML] AL amyloidosis: Unfolding a complex disease

R Lu, TA Richards - Journal of the advanced practitioner in …, 2019 - ncbi.nlm.nih.gov
Light chain (AL) amyloidosis is a rare plasma cell dyscrasia. An estimated 12,000 people
live with the disease in the United States. AL amyloidosis occurs from the misfolding of …

Amyloidosis: pathogenesis and new therapeutic options

G Merlini, DC Seldin, MA Gertz - Journal of Clinical Oncology, 2011 - ascopubs.org
The systemic amyloidoses are a group of complex diseases caused by tissue deposition of
misfolded proteins that results in progressive organ damage. The most common type …

High-dose melphalan and stem cell transplantation in AL amyloidosis with elevated cardiac biomarkers

PS White, P Phull, D Brauneis, JM Sloan… - Bone Marrow …, 2018 - nature.com
Immunoglobulin light-chain amyloidosis (AL amyloidosis) is a rare and often fatal disease
caused by misfolded light chains. These misfolded light chains form soluble toxic …

[HTML][HTML] Immunoglobulin light-chain amyloidosis: clinical presentations and diagnostic approach

YL Hwa, T Fogaren, A Sams, DV Faller… - Journal of the …, 2019 - ncbi.nlm.nih.gov
Systemic immunoglobulin light-chain (AL) amyloidosis is a rare disorder arising from a
plasma cell clone that produces misfolded immunoglobulin light chains, which are deposited …

[HTML][HTML] AL amyloidosis: advances in diagnosis and management

Y Koh - Blood research, 2020 - synapse.koreamed.org
Light chain (AL) amyloidosis is a disease in which malignant plasma cell clones affect
multiple organs including the heart and kidney. The mechanism for organ function …

[HTML][HTML] AL amyloidosis: current chemotherapy and immune therapy treatment strategies: JACC: CardioOncology state-of-the-art review

G Bianchi, Y Zhang, RL Comenzo - JACC: CardioOncology, 2021 - Elsevier
Immunoglobulin light chain (AL) amyloidosis is an incurable plasma cell disorder
characterized by deposition of fibrils of misfolded immunoglobulin free light chains (FLC) in …

Systemic Light Chain Amyloidosis

V Sanchorawala - New England Journal of Medicine, 2024 - Mass Medical Soc
Key Points Systemic Light Chain Amyloidosis Immunoglobulin light chain (AL) amyloidosis
is a rare disease that occurs when a plasma cell disorder produces monoclonal light chains …

[HTML][HTML] Systemic AL Amyloidosis and Precision Medicine

A Rüfer, R Schwotzer - healthbook …, 2021 - onco-hema.healthbooktimes.org
In amyloid light-chain (AL) amyloidosis, a small plasma-cell clone, or less frequently a
mature B-cell clone, produces toxic monoclonal light chains that can be deposited in the …

New insights and modern treatment of AL amyloidosis

CP Chaulagain, RL Comenzo - Current hematologic malignancy reports, 2013 - Springer
Systemic amyloidosis is a rare disease that is rarely cured. Systemic immunoglobulin light-
chain amyloidosis (AL) is the most common type, usually the result of monoclonal light …